SPOTLIGHT: King asks FDA to block ZymoGenetics' drug


King Pharmaceuticals has petitioned the FDA not to approved ZymoGenetics' rThrombin, a treatment for surgical bleeding. King claims that ZymoGenetics' drug has not been sufficiently tested and that it poses a risk to the public if approved. Why is King so interested? Well, because the company makes a competing version of the drug and stands to lose market share if a new version of the product is approved. If the FDA takes the request into account, it could be a major setback for ZymoGenetics. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.